[Phase II study of edobacomab (E5) in the treatment of gram-negative sepsis]

Autor: Hiroyuki KOBAYASHI, Shin KAWAI, Susumu SAKAYORI, Masamitsu KANEKO, Yasushi ITO, Yoshihito UJIIE, Kenji KOBAYASHI, Hitoshi IMAIZUMI, Shuitsu HOSHI, Shigeatsu ENDO, Ryouichi MOTOKI, Hitoshi INOUE, Gouichi ENDO, Masaaki ARAKAWA, Kouichi WADA, Hiroyuki HIRASAWA, Shigeto ODA, Hidetoshi SHIGA, Kunio KOBAYASHI, Takashi HIGO, Otohiko KUNII, Yasuo ONO, Hajime NISHIYA, Takeshi SATO, Kyuya ISHIBIKI, Masakazu UEDA, Kaoru SHIMADA, Satoshi KIMURA, Iwao KOMURO, Hajime GOTO, Takashi INAMATSU, Makiko FUKAYAMA, Izumi HAYASHI, Masao ICHIKI, Shuji SHIMAZAKI, Tetsuo YUKIOKA, Shoichi OOTA, Yasuyuki YONEDA, Takashi OOWADA, Katsuhiko SUGIMOTO, Shoichiro IRIMAJIRI, Yasuo OOSONE, Jyun TAKEZAWA, Toshio FUKUOKA, Jirou YURA, Nagao SHINAGAWA, Shu ISHIKAWA, Hirotada KATSUYA, Kiyoshi ISHIKAWA, Toshiyuki YAMAMOTO, Kanzou SUZUKI, Touru MATSUURA, Ikuto YOSHIYA, Nobuyuki TAENAKA, Kikushi KATSURADA, Hiroshi NISHIO, Keiji KUMON, Naoki YAHAGI, Ikuto SAKATA, Jirou MARUYAMA, Hiroshi TANIMURA, Makoto IWAHASHI, Shizuma MIZOBATA, Masahiro SHINOZAKI, Toshio NAKA, Chiiho FUJII, Mitsuhiro FUKUDA, Shinichi ISHIMATSU, Rinzo SOEJIMA, Yoshihito NIKI, Hiroshi TATARA, Takashi YOKOYAMA, Takashi KODAMA, Hiroaki TSUMURA, Katsurou YAGAWA, Nobuo KAKU, Mitsuo SOU, Toshimi TSUNEYOSHI, Kohei HARA, Shigeru KOHNO, Hironobu KOGA, Kazunori TOMONO, Yuuichi INOUE, Takakazu OTSUBO, Sadahiro ASAI, Hideo MASHIMOTO, Shouichi SATO, Jun ARAKI, Michio OGAWA, Satoshi IKEI, Masao YOSHIDA, Katsuya INADA, Kenji TADOKORO
Rok vydání: 1994
Předmět:
Zdroj: Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases. 68(1)
ISSN: 0387-5911
Popis: The efficacy, safety and usefulness of murine anti-endotoxin monoclonal IgM antibody "E5, an intravenous dose of 2 mg/kg" were evaluated in 88 patients with suspected Gram-negative sepsis from 37 institutes in Japan. Out of these, 74 patients were evaluable for the efficacy, 85 for safety and 75 for clinical usefulness. In assessing the efficacy, the patients were divided into 3 groups based on the plasma endotoxin levels (Endospecy with new PCA treatment of plasma): H group with a level of above 9.8 pg/ml and M group with a level of 3.0-9.8 pg/ml and L group with a level of below 3.0 pg/ml. 1. The efficacy rates as assessed following administration of E5 were 73.1% in the H group, 70.4% in the M group and 38.1% in the L group being higher in the groups with significantly high plasma endotoxin levels. 2. In both the H and M groups in whom plasma endotoxin levels were significantly high, the majority of the patients showed rapid reduction of the levels after administration of E5. 3. In all groups, improvement in body temperature, pulse rate, blood TNF-alpha and blood IL-6 was observed after treatment with E5. In the H and M groups with an endotoxin level of > or = 3.0 pg/ml, improvement in platelet count as well as in CRP was noted. The H group showed also improvement in WBC. 4. Improvement in the shock score was noted in all the groups but was more outstanding in the H and M groups in the early stage of treatment. 5. Side effects were seen in 5 (5.9%) of 85 patients and all thought to be allergic in symptoms such as rash, itching, fever and flare. 6. The reaction to the prick test performed before administration of E5 was negative in all these 5 patients. For 3 of the 5 patients, anti-E5 IgE antibody was measured. In all of them, the IgE levels were higher than those of healthy controls. Also, in 47.6% of patients, an elevation of anti-E5 IgG antibody was noted two weeks after the administration. 7. Clinical laboratory abnormalities were observed in 3 (3.5%) of 85 patients. They were an elevation of S-GOT.S-GPT and lowering of BUN, increased Al-p and decreased CH50, increased neutrophilia (%) and were all slight in the degree of the changes. 8. The clinical usefulness of E5 was evaluated for 75 patients.(ABSTRACT TRUNCATED AT 400 WORDS)
Databáze: OpenAIRE
Externí odkaz: